Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell Ltd has announced the quotation of 1,455,911 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from July 10, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its growth initiatives in the regenerative medicine sector, potentially impacting its market positioning and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd operates in the biotechnology industry, focusing on the development and commercialization of regenerative medicine products. The company primarily provides innovative solutions for the repair and regeneration of soft tissue injuries, with a market focus on improving patient outcomes in musculoskeletal conditions.
Average Trading Volume: 1,087,913
Technical Sentiment Signal: Buy
Current Market Cap: A$298.1M
For a thorough assessment of OCC stock, go to TipRanks’ Stock Analysis page.